EGFR and carcinoma: Many human carcinomas have been found to constitutively activate MET via protein overexpression or gene amplification, which is associated with poorer survival11,12 and resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR mutant lung adenocarcinoma13.